Vedanta Biosciences Stock
Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome.
Sign up today and learn more about Vedanta Biosciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Vedanta Biosciences Stock
Vedanta Biosciences was founded by PureTech and a team of world renowned experts in immunology and microbiology. Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. Vedanta Biosciences’ proprietary approach leverages foundational discoveries in the field of mucosal immunology to generate safe and potent treatments that restore intestinal homeostasis acting via mechanisms that are orthogonal to all existing drug classes. By modulating the microbiome with this class of drugs, we have the opportunity to treat a range of autoimmune and inflammatory diseases in potentially new ways and impact the lives of patients.
Funding History
June 2016 | $50.0M |
---|---|
November 2017 | $5.4M |
Management
Scientific Co-Founder
Dan Littman
Scientific Co-Founder
Alexander Rudensky
Chief Executive Officer
Bernat Olle
Co-founder
David Steinberg
Co-Founder & Chair
Ruslan Medzhitov
Press
businesswire - Feb, 19 2024
Vedanta Biosciences Presents Progress from Two Defined Bacterial Consortia, VE303 for the Prevention of C. difficile ...businesswire - Feb, 19 2024
Vedanta Biosciences to Host Investor Meetings at the Wells Fargo Virtual Private Biotech Symposiumbusinesswire - Feb, 19 2024
Vedanta Biosciences' Key Microbiome Patents Fully Upheld in Three European Opposition Proceedingslabiotech - Jan, 26 2024
Microbiome therapeutics: are we ready for 3rd-gen ...businesswire - Jan, 26 2024
PureTech Health plc – Half-Year Report